Improved hemodynamic function and mechanical efficiency in congestive heart failure with sodium dichloroacetate

Cardiology Division, University of California Medical Center, San Francisco.

OBJECTIVES. The purpose of this study was to determine whether sodium dichloroacetate improves hemodynamic performance and mechanical efficiency in congestive heart failure. BACKGROUND. Congestive heart failure is associated with impaired hemodynamic performance and reduced mechanical efficiency. Dichloroacetate stimulates pyruvate dehydrogenase activity by inhibition of pyruvate dehydrogenase kinase, which results in inhibition of free fatty acid metabolism and stimulation of high respiratory quotient glucose and lactate consumption by the heart. Facilitation of glucose and lactate consumption with dichloroacetate should improve mechanical efficiency of the failing ventricle. METHODS. Ten patients with New York Heart Association functional class III to IV congestive heart failure were studied. Dichloroacetate (50 mg/kg body weight) was administered intravenously for 30 min, with measurements of hemodynamic variables, coronary sinus blood flow and blood gas, glucose and lactate levels for 2 h. The same patients were also given dobutamine (5 to 12.5 micrograms/kg per min) for comparison. RESULTS. Therapeutic levels of dichloroacetate were achieved (100 to 160 micrograms/liter of plasma). Myocardial consumption of lactate was stimulated from 29% to 37.4%. Forward stroke volumes increased (+5.3 ml/beat, p < 0.02), as did left ventricular stroke work (+1.8 g-m/m2 per beat, p < 0.02) and left ventricular minute work (from 1.38 to 1.55 kg-m/m2 per min, p < 0.01). Myocardial oxygen consumption decreased (from 19.3 to 16.5 ml/min, p = 0.06) as left ventricular minute work increased. Left ventricular mechanical efficiency thus improved from 15.2% to 20.6% (p = 0.03). Dobutamine administration resulted in the opposite trend with respect to myocardial lactate extraction (from 34% to 15.3%, p < 0.02). Stroke volume increased (+7.4 ml/beat, p = NS vs. dichloroacetate), as did left ventricular minute work (from 1.29 to 1.59 g-m/m2 per min, p < 0.01 vs. dichloroacetate) and myocardial oxygen consumption (from 18.6 to 21.0 ml/min, p = 0.06 vs. dichloroacetate). Left ventricular mechanical efficiency did not change with dobutamine administration (from 16.4% to 15.8%, p = NS). CONCLUSIONS. Dichloroacetate administration stimulates myocardial lactate consumption and improves left ventricular mechanical efficiency. Forward stroke volume and left ventricular minute work increase significantly, with a simultaneous reduction in myocardial oxygen consumption. Dobutamine administration results in similar hemodynamic improvements but with no change in left ventricular mechanical efficiency and with opposite effects on lactate metabolism. The opposing metabolic actions, yet similar hemodynamic responses, of dichloroacetate and dobutamine suggest that these agents may be complementary in the treatment of congestive heart failure.

This article has been cited by other articles:

				G. Fragasso, A. Salerno, G. Lattuada, A. Cuko, G. Calori, A. Scollo, F. Ragogna, F. Arioli, G. Bassanelli, R. Spoladore, et al. Effect of partial inhibition of fatty acid oxidation by trimetazidine on whole body energy metabolism in patients with chronic heart failure Heart, September 15, 2011; 97(18): 1495 - 1500. [Abstract] [Full Text] [PDF]

				C. F. Rueda-Clausen, J. S. Morton, G. D. Lopaschuk, and S. T. Davidge Long-term effects of intrauterine growth restriction on cardiac metabolism and susceptibility to ischaemia/reperfusion Cardiovasc Res, May 1, 2011; 90(2): 285 - 294. [Abstract] [Full Text] [PDF]

				T. Kato, S. Niizuma, Y. Inuzuka, T. Kawashima, J. Okuda, Y. Tamaki, Y. Iwanaga, M. Narazaki, T. Matsuda, T. Soga, et al. Analysis of Metabolic Remodeling in Compensated Left Ventricular Hypertrophy and Heart Failure Circ Heart Fail, May 1, 2010; 3(3): 420 - 430. [Abstract] [Full Text] [PDF]

				B. C. Bergman, T. Tsvetkova, B. Lowes, and E. E. Wolfel Myocardial glucose and lactate metabolism during rest and atrial pacing in humans J. Physiol., May 1, 2009; 587(9): 2087 - 2099. [Abstract] [Full Text] [PDF]

				A. T. Turer, R. D. Stevens, J. R. Bain, M. J. Muehlbauer, J. van der Westhuizen, J. P. Mathew, D. A. Schwinn, D. D. Glower, C. B. Newgard, and M. V. Podgoreanu Metabolomic Profiling Reveals Distinct Patterns of Myocardial Substrate Use in Humans With Coronary Artery Disease or Left Ventricular Dysfunction During Surgical Ischemia/Reperfusion Circulation, April 7, 2009; 119(13): 1736 - 1746. [Abstract] [Full Text] [PDF]

				L. D. Calvert, R. Shelley, S. J. Singh, P. L. Greenhaff, J. Bankart, M. D. Morgan, and M. C. Steiner Dichloroacetate Enhances Performance and Reduces Blood Lactate during Maximal Cycle Exercise in Chronic Obstructive Pulmonary Disease Am. J. Respir. Crit. Care Med., May 15, 2008; 177(10): 1090 - 1094. [Abstract] [Full Text] [PDF]

				G. E. Haddad, L. J. Saunders, S. D. Crosby, M. Carles, F. del Monte, K. King, M. R. Bristow, F. G. Spinale, T. E. Macgillivray, M. J. Semigran, et al. Human cardiac-specific cDNA array for idiopathic dilated cardiomyopathy: sex-related differences Physiol Genomics, April 1, 2008; 33(2): 267 - 277. [Abstract] [Full Text] [PDF]

				L. Zhou, H. Huang, C. L. Yuan, W. Keung, G. D. Lopaschuk, and W. C. Stanley Metabolic response to an acute jump in cardiac workload: effects on malonyl-CoA, mechanical efficiency, and fatty acid oxidation Am J Physiol Heart Circ Physiol, February 1, 2008; 294(2): H954 - H960. [Abstract] [Full Text] [PDF]

				V. Labinskyy, M. Bellomo, M. P. Chandler, M. E. Young, V. Lionetti, K. Qanud, F. Bigazzi, T. Sampietro, W. C. Stanley, and F. A. Recchia Chronic Activation of Peroxisome Proliferator-Activated Receptor-{alpha} with Fenofibrate Prevents Alterations in Cardiac Metabolic Phenotype without Changing the Onset of Decompensation in Pacing-Induced Heart Failure J. Pharmacol. Exp. Ther., April 1, 2007; 321(1): 165 - 171. [Abstract] [Full Text] [PDF]

				G. Fragasso, A. Palloshi, P. Puccetti, C. Silipigni, A. Rossodivita, M. Pala, G. Calori, O. Alfieri, and A. Margonato A Randomized Clinical Trial of Trimetazidine, a Partial Free Fatty Acid Oxidation Inhibitor, in Patients With Heart Failure J. Am. Coll. Cardiol., September 5, 2006; 48(5): 992 - 998. [Abstract] [Full Text] [PDF]

				G. D. Lopaschuk Optimizing cardiac Fatty Acid and glucose metabolism as an approach to treating heart failure. Seminars in Cardiothoracic and Vascular Anesthesia, September 1, 2006; 10(3): 228 - 230. [Abstract] [PDF]

				G. Fragasso, G. Perseghin, F. De Cobelli, A. Esposito, A. Palloshi, G. Lattuada, P. Scifo, G. Calori, A. Del Maschio, and A. Margonato Effects of metabolic modulation by trimetazidine on left ventricular function and phosphocreatine/adenosine triphosphate ratio in patients with heart failure Eur. Heart J., April 2, 2006; 27(8): 942 - 948. [Abstract] [Full Text] [PDF]

				Y. Liao, S. Takashima, H. Zhao, Y. Asano, Y. Shintani, T. Minamino, J. Kim, M. Fujita, M. Hori, and M. Kitakaze Control of plasma glucose with alpha-glucosidase inhibitor attenuates oxidative stress and slows the progression of heart failure in mice Cardiovasc Res, April 1, 2006; 70(1): 107 - 116. [Abstract] [Full Text] [PDF]

				W. C. Stanley, F. A. Recchia, and G. D. Lopaschuk Myocardial Substrate Metabolism in the Normal and Failing Heart Physiol Rev, July 1, 2005; 85(3): 1093 - 1129. [Abstract] [Full Text] [PDF]

				M. P. Chandler, J. Kerner, H. Huang, E. Vazquez, A. Reszko, W. Z. Martini, C. L. Hoppel, M. Imai, S. Rastogi, H. N. Sabbah, et al. Moderate severity heart failure does not involve a downregulation of myocardial fatty acid oxidation Am J Physiol Heart Circ Physiol, October 1, 2004; 287(4): H1538 - H1543. [Abstract] [Full Text] [PDF]

				J. J. Magner and D. Royston Heart failure Br. J. Anaesth., July 1, 2004; 93(1): 74 - 85. [Abstract] [Full Text] [PDF]

				D. S.H. Bell Heart Failure: A Serious and Common Comorbidity of Diabetes Clin. Diabetes, April 1, 2004; 22(2): 61 - 65. [Abstract] [Full Text] [PDF]

				D. S.H. Bell Heart Failure: The frequent, forgotten, and often fatal complication of diabetes Diabetes Care, August 1, 2003; 26(8): 2433 - 2441. [Abstract] [Full Text] [PDF]

				A. V Zima, J. Kockskamper, R. Mejia-Alvarez, and L. A Blatter Pyruvate Modulates Cardiac Sarcoplasmic Reticulum Ca2+ Release in Rats Via Mitochondria-Dependent and -Independent Mechanisms J. Physiol., August 1, 2003; 550(3): 765 - 783. [Abstract] [Full Text] [PDF]

				P. W. Stacpoole, N. V. Nagaraja, and A. D. Hutson Efficacy of Dichloroacetate as a Lactate-Lowering Drug J. Clin. Pharmacol., July 1, 2003; 43(7): 683 - 691. [Abstract] [Full Text] [PDF]

				G. D. Lopaschuk and M. Marzilli Mode of Action of Trimetazidine and Other New Metabolic Agents in the Treatment of Ischemic Heart Disease Seminars in Cardiothoracic and Vascular Anesthesia, March 1, 2003; 7(1): 91 - 96. [PDF]

				M. Bartnik, K. Malmberg, and L. Ryden Diabetes and the heart: compromised myocardial function -- a common challenge Eur. Heart J. Suppl., January 1, 2003; 5(suppl_B): B33 - B41. [Abstract] [PDF]

				M. P. Chandler, W. C. Stanley, H. Morita, G. Suzuki, B. A. Roth, B. Blackburn, A. Wolff, and H. N. Sabbah Short-Term Treatment With Ranolazine Improves Mechanical Efficiency in Dogs With Chronic Heart Failure Circ. Res., August 23, 2002; 91(4): 278 - 280. [Abstract] [Full Text] [PDF]

				G. D. Lopaschuk, I. M. Rebeyka, and M. F. Allard Metabolic Modulation: A Means to Mend a Broken Heart Circulation, January 15, 2002; 105(2): 140 - 142. [Full Text] [PDF]

				E. D. Michelakis, M. S. McMurtry, X.-C. Wu, J. R.B. Dyck, R. Moudgil, T. A. Hopkins, G. D. Lopaschuk, L. Puttagunta, R. Waite, and S. L. Archer Dichloroacetate, a Metabolic Modulator, Prevents and Reverses Chronic Hypoxic Pulmonary Hypertension in Rats: Role of Increased Expression and Activity of Voltage-Gated Potassium Channels Circulation, January 15, 2002; 105(2): 244 - 250. [Abstract] [Full Text] [PDF]

				H. N. Sabbaha and W. C. Stanley Partial fatty acid oxidation inhibitors: a potentially new class of drugs for heart failure Eur J Heart Fail, January 1, 2002; 4(1): 3 - 6. [Full Text] [PDF]

				B. Grassi, M. C Hogan, P. L Greenhaff, J. J Hamann, K. M Kelley, W. G Aschenbach, D. Constantin-Teodosiu, and L B. Gladden Oxygen uptake on-kinetics in dog gastrocnemius in situ following activation of pyruvate dehydrogenase by dichloroacetate J. Physiol., January 1, 2002; 538(1): 195 - 207. [Abstract] [Full Text] [PDF]

				R. T. Smolenski, M. Amrani, J. Jayakumar, P. Jagodzinski, C. C. Gray, A. T. Goodwin, I. A. Sammut, and M. H. Yacoub Pyruvate/dichloroacetate supply during reperfusion accelerates recovery of cardiac energetics and improves mechanical function following cardioplegic arrest Eur J Cardiothorac Surg, June 1, 2001; 19(6): 865 - 872. [Abstract] [Full Text] [PDF]

				M. Taylor, T. R. Wallhaus, T. R. DeGrado, D. C. Russell, P. Stanko, R. J. Nickles, and C. K. Stone An Evaluation of Myocardial Fatty Acid and Glucose Uptake Using PET with [18F]Fluoro-6-Thia-Heptadecanoic Acid and [18F]FDG in Patients with Congestive Heart Failure J. Nucl. Med., January 1, 2001; 42(1): 55 - 62. [Abstract] [Full Text] [PDF]

				H. Taegtmeyer Metabolism--the lost child of cardiology J. Am. Coll. Cardiol., October 1, 2000; 36(4): 1386 - 1388. [Full Text] [PDF]

				J. L. Griffin, L. T. White, and E. D. Lewandowski Substrate-dependent proton load and recovery of stunned hearts during pyruvate dehydrogenase stimulation Am J Physiol Heart Circ Physiol, July 1, 2000; 279(1): H361 - H367. [Abstract] [Full Text] [PDF]

				W. C Stanley and C. L Hoppel Mitochondrial dysfunction in heart failure: potential for therapeutic interventions? Cardiovasc Res, March 1, 2000; 45(4): 805 - 806. [Full Text] [PDF]

				D. Constantin-Teodosiu, E. J. Simpson, and P. L. Greenhaff The importance of pyruvate availability to PDC activation and anaplerosis in human skeletal muscle Am J Physiol Endocrinol Metab, March 1, 1999; 276(3): E472 - E478. [Abstract] [Full Text] [PDF]